<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178450</url>
  </required_header>
  <id_info>
    <org_study_id>01PTHi</org_study_id>
    <secondary_id>2008-007017-76</secondary_id>
    <nct_id>NCT01178450</nct_id>
  </id_info>
  <brief_title>Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation</brief_title>
  <official_title>A Prospective, Randomized Trial to Compare Subtotal Parathyroidectomy Versus Cinacalcet in the Treatment of Persistent Secondary Hyperparathyroidism Post Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Josep M Cruzado</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that subtotal parathyroidectomy using minimally invasive
      surgery is superior to cinacalcet for the treatment of persistent secondary
      hyperparathyroidism (HPT) post renal transplant, with minimal morbidity and significantly
      reduces the cost of treatment post transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent hyperparathyroidism (HPT) with hypercalcemia is prevalent after transplant
      (affects up to 25% of patients) and negatively affects graft and patient outcome. The
      subtotal parathyroidectomy is the standard treatment, although currently has been replaced by
      the calcimimetic cinacalcet. Several studies guarantee that cinacalcet is effective in
      controlling hypercalcemia derived of persistent HPT after renal transplantation. However,
      maintenance treatment is need because hypercalcemia increases quickly after treatment is
      stopped. This fact makes increase a lot the cost of transplantation in these patients.

      The hypothesis of this study is that subtotal parathyroidectomy by minimally invasive surgery
      is superior to cinacalcet for treatment of persistent secondary HPT post renal transplant,
      with minimal morbidity and significantly reduces the cost of treatment after transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood calcium levels</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in blood calcium levels at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in parathyrin blood levels</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in parathyrin blood levels at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>12 months</time_frame>
    <description>Patient and graft survival between inclusion and month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic evaluation of interventions measured by money spend in it.</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of economic evaluations of both interventions between inclusion and month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate.</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in glomerular filtration rate at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood calcium levels</measure>
    <time_frame>3 months</time_frame>
    <description>Change from baseline in blood calcium levels at 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood calcium levels</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in blood calcium levels at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in parathyrin blood levels</measure>
    <time_frame>3 months</time_frame>
    <description>Change from baseline parathyrin blood levels at 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in parathyrin blood levels</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline parathyrin blood levels at 6 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Subtotal parathyroidectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cinacalcet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Subtotal parathyroidectomy</intervention_name>
    <description>The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland</description>
    <arm_group_label>Subtotal parathyroidectomy</arm_group_label>
    <other_name>Parathyroidectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cinacalcet</intervention_name>
    <description>Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia</description>
    <arm_group_label>Cinacalcet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Functioning renal transplant, GFR ≥ 30 ml / min

          -  Time post-transplant&gt; 6 months

          -  PTHi&gt;15pmol/L

          -  Calcium ≥2.63 mmol/L con phosphatemia ≤1.2 mmol/L

          -  Cervical scintigraphy

          -  Signed informed consent

        Exclusion Criteria:

          -  Contraindication to surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep M Cruzado, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nephrology Department. Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Moreno, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Surgery Department. Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelone</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Josep M Cruzado</investigator_full_name>
    <investigator_title>Nephrologist</investigator_title>
  </responsible_party>
  <keyword>Renal transplant</keyword>
  <keyword>Hypercalcemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cinacalcet Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

